Organization · Micro VC
Valence Life Sciences
Valence Life Sciences is a New York-based venture capital firm specializing in late-stage private and micro-cap public drug development companies within the life sciences sector.
Overview
What Valence Life Sciences does
What Valence Life Sciences is
Valence Life Sciences is a New York-based venture capital firm specializing in late-stage private and micro-cap public drug development companies within the life sciences sector.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Micro VC
- Founded
- Founded in 2012
- Approximate age
- About 14 years
- Structured capabilities
- Funder
- Last reviewed
- May 4, 2026
Official channels
Find Valence Life Sciences elsewhere
Open the official website or a supported primary organization account.
Capability profile
Valence Life Sciences as a funder
Investment thesis
Valence Life Sciences invests in late-stage private and micro-cap public drug development companies, focusing on capital-intensive phases of biotech lifecycles.
Focus narrative
Valence Life Sciences concentrates on investments in the life sciences sector, particularly in late-stage private and micro-cap public biotech companies. The firm seeks to provide strategic capital to support clinical milestones and facilitate transitions from private to public ownership.
Value beyond capital
Valence Life Sciences adds value to its portfolio companies by providing strategic capital during critical phases of development, facilitating transitions to public markets, and leveraging its expertise in the biotech sector to support clinical milestones.
Focus and fit
- Stages
- Series C · Series D · Growth Equity
- Regions
- North America · Global
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 3
- Recorded notable exits
- Atea Pharmaceuticals
Portfolio context
Notable portfolio companies include: Atea Pharmaceuticals (NASDAQ: AVIR): A clinical-stage biotech focused on antiviral drug development for hepatitis C and other viral diseases. Leap Therapeutics (NASDAQ: LPTX): A clinical-stage immuno-oncology biotech company. CalciMedica: A clinical-stage biotech developing calcium release-activated calcium channel inhibitors for inflammatory diseases.
Common questions
What to know about Valence Life Sciences
Upseed classifies Valence Life Sciences under the Micro VC organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
May 4, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.